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Introduction: Microalbuminuria in type 1 diabetes is the earliest manifestation of diabetic microangiopathy
(nephropathy). To date, the pharmacological approach to microangiopathy has not been shown to be useful. By
using aminaphtone to control nephrologic complications of insulin-dependent diabetes mellitus we first obtained a
significant improvement in microalbuminuria confirming this new pharmacological approach for insulin-dependent
diabetes mellitus organospecific complications control.
Case presentation: After being treated with standard therapy for insulin-dependent diabetes mellitus (insulin) for
more than 20 years, a 49-year-old white man affected by insulin-dependent diabetes mellitus adopted the standard
therapy aminaphtone for a period of 2 months.
This therapy allowed a significant reduction of proteinuria from baseline evaluation that immediately increased after
he stopped aminaphtone therapy.
Conclusions: Aminaphtone therapy, used globally in the treatment and prevention of endothelial dysfunctions,
could be an interesting option for patients with insulin-dependent diabetes mellitus with the express purpose of
preventing diabetic nephropathy.
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Microangiopathic complications of diabetes include ret-
inopathy, nephropathy and neuropathy. These complica-
tions are specific to diabetes and arise as a result of
hyperglycaemia that lasts a long time. Undoubtedly, other
metabolic factors, and environmental and genetic factors
are involved in the pathogenesis. Diabetic nephropathy
affects 20 to 40% of patients with insulin-dependent
diabetes mellitus (IDDM), particularly those with onset
before puberty [1] and, probably, those with a hereditary
predisposition to hypertension [2]. Patients with diabetes
with incipient nephropathy (persistent microalbuminuria)
have a 5 to 10 times greater risk of developing proliferative
retinopathy than those without albuminuria; furthermore,
diabetic nephropathy is almost invariably accompanied
by retinopathy. The functional alterations that occur
early in the natural history of diabetic nephropathy
include microalbuminuria and glomerular hyperfiltration.* Correspondence: bertini@baldaccilab.com
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unless otherwise stated.Microalbuminuria is defined as a subclinical increase in
the rate of urinary albumin excretion in the range of 30
to 300mg/day. Microalbuminuria is due to the increased
permeability of the glomerular capillaries, probably sec-
ondary to increased glomerular capillary pressure [3] and
to the loss of negative charge at the level of the glomerular
basement membrane.
Patients with IDDM with microalbuminuria have a 20
times greater risk of developing a clinical nephropathy
compared to those with a normal albumin excretion [4].
Microalbuminuria is considered a risk factor for diabetic
nephropathy and progressive renal failure in diabetes
[5-8]. Longitudinal and cross-sectional studies conducted
on type 2 diabetes have allowed the identification of risk
factors associated with the development of microalbumi-
nuria and the progression of microalbuminuria to diabetic
nephropathy. These include: low body mass index, early
onset of diabetes, hyperglycaemia, hypertension, dyslipi-
daemia, cigarette smoking, and a family history of hyper-
tension [9-14]. Although microalbuminuria is considered
by many authors to be the early stage of an irreversible
process, recent research has not confirmed this view,l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Periungual videocapillaroscopic: microbleeds spread
“pearl parades”.
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normal value [15,16]. The histopathological features charac-
teristic of diabetic kidney disease occur in the glomerulus.
The main changes are: increase in the thickening of the
glomerular basement membrane, increase of volume of the
mesangium, the presence of hyaline deposits and global
glomerular sclerosis [17]. The glomerular filtration rate
(GFR) is closely related to the surface of the basal mem-
brane of the glomerular capillaries (filtration surface) which
is in turn determined by the number of clusters present at
the time of diagnosis, the entity of the expansion of the
mesangium, the expansion capacity and the number of
sclerotic glomeruli. Urinary albumin excretion is related to
the size of the pores of filtration. The vascular endothelium
plays a central role in the regulation of vascular tone.
Endothelin (ET) is a potent vasoconstrictor produced by
endothelium that contributes to basal vascular tone. Vaso-
constriction in response to altered endogenous ET may
lead to hyperperfusion and subsequent microvascular
damage. Hyperperfusion is one of the keys to the onset
and progression of microvascular complications in dia-
betes. Such a haemodynamic condition can be determined
by the excessive release of vasodilator substances, as for
example during ketonic decompensation, or for a reduced
action of vasoconstrictive substances. This interpretation
may be the pathophysiological basis of what has been
observed in diabetes. In patients with diabetes there is a
deficit of action of ET that, unlike in the normal patient,
does not induce vasoconstriction. In fact, individuals with
diabetes have levels of ET that would appear to be deter-
mined mainly by triglycerides and insulin.
Aminaphtone (2-hydroxy-3-methyl-1,4-napthohydroqui-
none-2-p-aminobenzoate) is a synthetic molecule derived
from four aminobenzoic acids which is currently employed
for “capillary disorders” and for chronic venous insuffi-
ciency [18]. This drug has recently demonstrated the ability
to downregulate ET-1 production in ECV304 cells by
interfering with transcription of preproET-1 (PPET-1) gene
expression [19]. At the same time, cytofluorometry has
shown that aminaphtone significantly reduces the expres-
sion of E-selectin (endothelial-leukocyte adhesion mol-
ecule 1; ELAM-1) both in resting and in ET-B -activated
ECV304 cells in a dose-dependent manner [20]. In vivo,
in patients affected by systemic sclerosis, 12 weeks of
aminaphtone treatment has demonstrated the ability to
downregulate sELAM-1 (soluble E-selectin adhesion
molecules 1) and sVCAM-1 (soluble vascular cell adhesion
molecule 1) [21]. In a rat model of monocrotaline-induced
pulmonary hypertension, the administration of aminaph-
tone (30mg/kg/day or 150mg/kg/day) significantly lowered
rat mortality and significantly reduced plasma ET-1 con-
centration [22]. Aminaphtone has also demonstrated anti-
phlogistic activity on endothelial cells [23]. In order to
control vascular microangiopathy in patients affected byIDDM with proteinuria and hypertension, we added ami-
naphtone to standard therapy for IDDM (insulin) and
hypertension (angiotensin-converting enzyme inhibitors).Case presentation
A 49-year-old white man with type 1 diabetes has, from the
age of 20, been treated with NovoRapid® (insulin aspart;
3U breakfast time, 8U lunch time, and 10U dinner time)
and Lantus® (insulin glargine; 14U 10 p.m.) for glycaemic
control for more than 20 years. He has been hypertensive
since 2006 and receives treatment with ramipril: one
tablet 5mg at breakfast time. He has also been treated
with Torvast (atorvastatin; one tablet 10mg/day) for
hypercholesterolaemia. Microalbuminuria has been present
in this patient since 2006 independently of any pharma-
cological treatments; no alterations have been reported
in his fundus oculi during the time. An examination of
his nailfold periungual videocapillaroscopy shows the
presence of beanpole loops with dilated venous tract
and presence of pearl-like microbleeds with clear signs
of microangiopathy (Figure 1). His microalbuminuria
value was 487.1mg/L; GFR was under 58mL/minute;
creatinine was 1.31mg/dL and arterial blood pressure
was 140/85mmHg. He began treatment with aminaph-
tone 75mg one tablet twice a day for 2 months. After 2
months of therapy he was re-evaluated by videocapil-
laroscopic examination showing a clear resolution of
profuse bleeding (Figure 2). At the same time his micro-
albuminuria value significantly decreased (98.3mg/L); his
GFR (under 57mL/minute) and creatinine (1.33mg/dL)
were substantially unchanged but his arterial blood pres-
sure decreased to 130/80mmHg. Taking into account the
results obtained with the above treatment, he continues to
take aminaphtone; however, intake was spontaneously
interrupted for 2 months. After 2 months without ami-
naphtone treatment he repeated proteinuria evaluation:
his microalbuminuria significantly increased to 573.0mg/L
while his GFR (under 58mL/minute) and creatinine
(1.31mg/dL) were unchanged and his arterial blood
pressure again increased to 140/85mmHg. No side
effects related to aminaphtone were detected during
the trial.
Figure 2 Periungual videocapillaroscopic: resolution of
profuse bleeding.
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This case report initially describes a significant reduction
of proteinuria in a patient with diabetes type 1, due to
the use of aminaphtone. Our patient was first evaluated
after 2 months of treatment (aminaphtone capsules 75mg
twice a day), showing a significant decrease in microalbu-
minuria (from 487.1mg/dL to 98.3mg/dL = −388.8mg/dL)
confirmed by an improvement in the capillaroscopic
examination, while GFR and creatinine remained sub-
stantially unchanged. Surprisingly, arterial blood pressure
decreased from 140/85mmHg to 130/80mmHg after
treatment. Subsequently, he continued treatment with
aminaphtone for 2 months, but spontaneously interrupted
the treatment. He was re-evaluated 2 months after discon-
tinuation of the drug and, again, showed an increase in pro-
teinuria (from 98.3mg/dL to 573mg/dL = +474.7mg/dL),
substantially the same GFR and creatinine values, and a
new increase in arterial blood pressure to 140/85mmHg:
this kind of re-challenge clearly demonstrates the relation-
ship between proteinuria and aminaphtone therapy. The
recent preclinical findings about aminaphtone (anti-ET-1
and anti-E-selectin activities together with a significant
endothelial antiphlogistic effect) [19-23] seem to correlate
with this result, confirming that microangiopathy is the
leading cause of microalbuminuria in patients with IDDM.
Conclusions
Aminaphtone therapy seems to be useful for proteinuria
control in patients with type 1 diabetes. The correlation
between proteinuria and arterial blood pressure that
significantly decreased after aminaphtone treatment and
increased once treatment was stopped was surprising.
To the best of our knowledge, descriptions of aminaph-
tone’s activity have not included a report of a novel
therapeutic option. For the purposes of therapeutic effect-
iveness, the duration of treatment (more than 2 months)
together with the compliance of daily administration of
the drug appears to be relevant. Further controlled stud-
ies, including randomised double-blind controlled trials,
are needed to definitively evaluate aminaphtone’s efficacy
over the long term in patients with IDDM. Nevertheless,
the lesson to take from this case report is that a pharma-
cological treatment of diabetic microangiopathy with avascular drug like aminaphtone could be useful for protein-
uria control postponing IDDM nephrologic complications.
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Written informed consent was obtained from the patient
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